SRR10842360
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MITOTIC_SPINDLE+0.400
- E2F_TARGETS+0.300
- G2M_CHECKPOINT+0.300
- MYC_TARGETS_V2+0.300
- PROTEIN_SECRETION+0.200
- UV_RESPONSE_DN+0.200
- WNT_BETA_CATENIN_SIGNALING+0.200
- APICAL_JUNCTION+0.100
- DNA_REPAIR+0.100
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.100
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.400
- IL6_JAK_STAT3_SIGNALING-0.400
- OXIDATIVE_PHOSPHORYLATION-0.400
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.400
- TNFA_SIGNALING_VIA_NFKB-0.400
- APICAL_SURFACE-0.300
- APOPTOSIS-0.300
- COMPLEMENT-0.300
- IL2_STAT5_SIGNALING-0.300
- INFLAMMATORY_RESPONSE-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | C3N-02435 | — | cohortSQ1 | 0.845 |
| 2 | TCGA-56-8083-01A-11R-2247-07 | — | cohortMD1 | 0.830 |
| 3 | b985822b-8c9c-4e26-9f11-4f5dbe736518 | — | — | 0.824 |
| 4 | BS_9FHSNVS0 | ATRT | — | 0.816 |
| 5 | SRR10899974 | — | — | 0.814 |
| 6 | TCGA-50-6591-01A-11R-1755-07 | — | cohortMD1 | 0.806 |
| 7 | SRR6013547 | — | cohortMD1 | 0.804 |
| 8 | C3N-03886 | — | cohortMD1 | 0.803 |
| 9 | BSR_21_0015_A1_S76 | — | B | 0.801 |
| 10 | SRR9879265 | — | cohortMD1 | 0.799 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 11 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MITOTIC_SPINDLE | 0.400 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.300 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.300 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.300 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.200 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.200 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.200 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.100 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.100 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.100 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.100 | Inavolisib | — uncovered |